KC-2684

NIH/3T3-cKit-AY502-3dup-Cell-Line

×
26571
Home » Cell Lines » NIH/3T3-cKit-AY502-3dup-Cell-Line

Background of NIH/3T3-cKit-AY502-3dup-Cell-Line

KIT (also known as c-Kit, CD117, and stem cell factor receptor) is a type III receptor tyrosine kinase. Ligand-dependent KIT signaling regulates hematopoietic, mast-cell, melanocyte and germ-cell biology. Activating KIT alterations can confer ligand-independent signaling and are recurrent oncogenic drivers in gastrointestinal stromal tumors and other malignancies.

Specifications

Catalog NumberKC-2684
Cell Line NameNIH/3T3-cKit-AY502-3dup-Cell-Line
NCBI/UniProt Accession NumberNM_000222.3
Host Cell LineNIH/3T3
DescriptionA stable NIH/3T3 cell line expressing human KIT with an AY502-503 duplication for cKIT inhibitor studies
QuantityOne vial of frozen cells (≥2×106 cells)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% DMEM+20% FBS+10% DMSO
Propagation MediumDMEM+10%FBS+2µg/mL Puromycin
Selection MarkerPuromycin
MorphologyFibroblast-like
SubcultureSplit saturated culture at a ratio of 1:10 every 3 days
Incubation37 °C with 5% CO₂
StorageLiquid nitrogen immediately upon receiving
Doubling TimeEstimated 20 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

NIH/3T3-cKIT-AY502-3dup cell line was generated using a retroviral vector expressing the human cKIT-AY502-3dup sequence.

Characterization

Figure 1: Characterization of the human cKIT-AY502-3dup sequence in NIH/3T3-cKIT-AY502-3dup stable cells using Sanger sequencing.

Figure 2: Characterization of NIH/3T3-cKIT-AY502-3dup cell response to cKIT inhibitors following 72-hour treatment using a cell viability assay.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into an appropriate culture vessel.
  7. Incubate the cells at 37°C in a humidified 5% CO₂ incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh complete medium without selective antibiotic.
  9. Subculture the cells at a ratio of 1:10 every 3 days.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

  1. Sartini S, et al. Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview. Curr Med Chem. 2011;18(19):2893-2903.
  2. Boikos SA, et al. Gastrointestinal Stromal Tumors: The GIST of Precision Medicine. Trends Cancer. 2018;4(1):74-91.
  3. Isozaki K, Hirota S. Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors. Curr Genomics. 2006;7(8):469-475.

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.